Company Profile
MediWound Stock Price, News & Analysis
- Ticker:
- MDWD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
14.28 USD (+0.63%)
Close
Last updated: August 6, 2026
177M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MDWD closed up 0.63% at $14.28. No new same-company headline was identified in the current news window.
Company overview
Enzymatic Tissue Repair Company
MediWound develops non-surgical enzymatic therapies for tissue repair. Its approved product NexoBrid is used for enzymatic removal of burn eschar and is commercialized in the United States, European Union, Japan, and other international markets.
NexoBrid Commercial Foundation
NexoBrid is an approved enzymatic debridement product with established use in specialized burn care. Regional commercialization through partners gives MediWound product revenue and market access while the company continues investing in broader supply capacity.
Emergency Preparedness Role
NexoBrid also has strategic applications in national preparedness and military medicine. A BARDA-supported contract with Vericel covers procurement, inventory management, potential blast-trauma development, and next-generation manufacturing capacity.
EscharEx Chronic Wound Pipeline
EscharEx is a late-stage enzymatic debridement candidate for chronic wounds, including venous leg ulcers, diabetic foot ulcers, and pressure ulcers. MediWound is positioning it as a potential next-generation standard for chronic wound debridement.
Manufacturing and Supply Expansion
MediWound is expanding NexoBrid production capacity to support commercial demand and strategic stockpiling. Regulatory qualification of the enlarged facility is important to the company’s ability to supply additional markets and government preparedness programs.
Future catalysts
A prespecified interim sample-size reassessment and completion of enrollment in the Phase 3 VALUE study of EscharEx are expected by the end of the first quarter of 2027.
Commercial supply from the expanded NexoBrid manufacturing facility remains subject to regulatory approval, with modifications responding to EMA pre-audit recommendations expected in the second half of 2026.
Recent news
- 01
MediWound to Report Second Quarter 2026 Financial Results
Source: MediWound
- 02
- 03
MediWound to Report First Quarter 2026 Financial Results
Source: MediWound
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MediWound (MDWD)?
MediWound (MDWD) most recently closed at 14.28 USD, a +0.63% move versus the previous session.
What is the market cap of MediWound (MDWD)?
MediWound currently has a market capitalization of 177M USD on BioPharmSignal.
What does MediWound do?
Enzymatic Tissue Repair Company MediWound develops non-surgical enzymatic therapies for tissue repair. Its approved product NexoBrid is used for enzymatic removal of burn eschar and is commercialized in the United States, European Union, Japan, and other international markets. NexoBrid Commercial Foundation NexoBrid is an approved enzymatic debridement...
On which exchange is MDWD stock listed?
MediWound (MDWD) is associated with NASDAQ, Israel, Biopharma.
What is Enzymatic?
Enzymatic Tissue Repair Company MediWound develops non-surgical enzymatic therapies for tissue repair.
Which conditions is MediWound targeting with Enzymatic?
Enzymatic Tissue Repair Company MediWound develops non-surgical enzymatic therapies for tissue repair. Its approved product NexoBrid is used for enzymatic removal of burn eschar and is commercialized in the United States, European Union, Japan, and other international markets. NexoBrid Commercial Foundation NexoBrid is an approved enzymatic debridement...
How does MediWound describe recent progress with Enzymatic?
A prespecified interim sample-size reassessment and completion of enrollment in the Phase 3 VALUE study of EscharEx are expected by the end of the first quarter of 2027. Commercial supply from the expanded NexoBrid manufacturing facility remains subject to regulatory approval, with modifications responding to EMA pre-audit recommendations expected in the...
What is Tissue?
Enzymatic Tissue Repair Company MediWound develops non-surgical enzymatic therapies for tissue repair.